Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PTX COVID19 B

Next Previous
Drug Profile

PTX COVID19 B

Alternative Names: PTX-COVID19-B

Latest Information Update: 11 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Providence Therapeutics
  • Developer Everest Medicines; Providence Therapeutics
  • Class COVID-19 vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued COVID 2019 infections

Most Recent Events

  • 11 Nov 2025 PTX COVID19 B is available for licensing as of 11 Nov 2025. https://providencetherapeutics.com/business-development/partnerships.html (Providence Therapeutics email communication, November 2025)
  • 18 Feb 2024 Everest Medicines plans to terminate its licence for PTX COVID19 B
  • 29 Mar 2023 Providence Therapeutics Holdings completes a Phase-II trial in COVID-2019 infections (Prevention) in Canada and South Africa (IM, Injection) (NCT05175742)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top